Physician profile
Mohammad O Hussaini
NPI 1053503847
$77,061.32
in general payments reported to CMS, 2019-2025
9 companies · $7,686 in 2025
The $7,686 reported for 2025 was more than what 99% of Molecular Genetic Pathology (Medical Genetics) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,185 · 2020: $23K · 2021: $7,146 · 2022: $25K · 2023: $4,682 · 2024: $3,265 · 2025: $7,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Travel and Lodging: $1,897 · Food and Beverage: $77.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,658.00 |
| Travel and Lodging | $1,897.46 |
| Food and Beverage | $77.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adaptive Biotechnologies Corporation | $34,247.39 | 2019-2025 | Clonoseq |
| Blueprint Medicines Corporation | $12,675.81 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $10,845.44 | 2022-2024 | |
| Amgen INC. | $6,996.00 | 2020-2021 | |
| Stemline Therapeutics INC. | $6,081.42 | 2019 | |
| Abbvie INC. | $2,750.00 | 2023 | |
| Celgene Corporation | $2,248.78 | 2020-2024 | |
| Seagen INC. | $1,125.00 | 2020 | |
| Foundation Medicine, INC. | $91.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Hussaini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.